• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Poll: Where Do You Stand on Product Exclusivity Protections?

Article

When it comes to biologics, there is a constant push and pull over patent rights. Some believe this is part of a healthy market-driven economy. Others are skeptical.

What best describes your opinion about the US patent system as it relates to biologics medicine?

It ensures that innovator companies are rewarded fairly and incentivized to develop new medicines.
Patents issued after a product receives FDA approval should be limited.
Concerns about patents preventing biosimilar competition are exaggerated.
Patents have burdened the health care system with high costs and lack of competition.

Newsletter

Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.

Recent Videos
Canavan & O’Dell
global biosimilars week join the movement
Ha Kung Wong, JD
© 2025 MJH Life Sciences

All rights reserved.